Rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, restores alveolar and pulmonary vascular development in a rat model of bronchopulmonary dysplasia

Yonsei Medical Journal

Volumn 55, Issue 1, 2014, Pages 99-106

  Lee, Hyun Ju ^a   Lee, Youn Jin ^b,c   Choi, Chang Won ^b,c   Lee, Jin A ^c   Kim, Ee Kyung ^c   Kim, Han Suk ^c   Kim, Beyong Il ^b,c   Choi, Jung Hwan ^c  

^a Hanyang University   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

Alveolarization; Bronchopulmonary dysplasia; Peroxisome proliferator activated receptor ; Rosiglitazone

Indexed keywords

CD31 ANTIGEN; LIPOPOLYSACCHARIDE; ROSIGLITAZONE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HEART RIGHT VENTRICLE HYPERTROPHY; HISTOLOGY; HYPEROXIA; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; LUNG DEVELOPMENT; LUNG DYSPLASIA; MALE; MICROSCOPY; MORPHOMETRICS; NEWBORN; NONHUMAN; PREGNANCY; RAT; VASCULARIZATION; WESTERN BLOTTING;

ALVEOLARIZATION; BRONCHOPULMONARY DYSPLASIA; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-Γ; ROSIGLITAZONE;

ANIMALS; BRONCHOPULMONARY DYSPLASIA; FEMALE; HYPERTENSION, PULMONARY; IMMUNOHISTOCHEMISTRY; LUNG; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES; VASODILATOR AGENTS;

EID: 84890620046     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2014.55.1.99     Document Type: Article

References (34)

1. Philip AG. Bronchopulmonary dysplasia: then and now. Neonatology 2012;102:1-8.
2. Hartling L, Liang Y, Lacaze-Masmonteil T. Chorioamnionitis as a risk factor for bronchopulmonary dysplasia: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2012;97:F8-17.
3. Saugstad OD. Oxygen and oxidative stress in bronchopulmonary dysplasia. J Perinat Med 2010;38:571-7.
4. Speer CP. Inflammation and bronchopulmonary dysplasia: a continuing story. Semin Fetal Neonatal Med 2006;11:354-62.
5. Torday JS, Rehan VK. The evolutionary continuum from lung development to homeostasis and repair. Am J Physiol Lung Cell Mol Physiol 2007;292:L608-11.
6. McGowan SE, Torday JS. The pulmonary lipofibroblast (lipid interstitial cell) and its contributions to alveolar development. Annu Rev Physiol 1997;59:43-62.
7. Rehan VK, Wang Y, Patel S, Santos J, Torday JS. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, prevents hyperoxia-induced neonatal rat lung injury in vivo. Pediatr Pulmonol 2006;41:558-69.
8. Dasgupta C, Sakurai R, Wang Y, Guo P, Ambalavanan N, Torday JS, et al. Hyperoxia-induced neonatal rat lung injury involves activation of TGF-{beta} and Wnt signaling and is protected by rosiglitazone. Am J Physiol Lung Cell Mol Physiol 2009;296:L1031-41.
9. Wang Y, Santos J, Sakurai R, Shin E, Cerny L, Torday JS, et al. Peroxisome proliferator-activated receptor gamma agonists enhance lung maturation in a neonatal rat model. Pediatr Res 2009;65:150-5.
10. Lee HJ, Kim BI, Choi ES, Choi CW, Kim EK, Kim HS, et al. Effects of postnatal dexamethasone or hydrocortisone in a rat model of antenatal lipopolysaccharide and neonatal hyperoxia exposure. J Korean Med Sci 2012;27:395-401.
11. Choi CW, Kim BI, Hong JS, Kim EK, Kim HS, Choi JH. Bronchopulmonary dysplasia in a rat model induced by intra-amniotic inflammation and postnatal hyperoxia: morphometric aspects. Pediatr Res 2009;65:323-7.
12. Fulton RM, Hutchinson EC, Jones AM. Ventricular weight in cardiac hypertrophy. Br Heart J 1952;14:413-20.
13. Lee HJ, Choi CW, Kim BI, Kim EK, Kim HS, Choi JH, et al. Serial changes of lung morphology and biochemical profiles in a rat model of bronchopulmonary dysplasia induced by intra-amniotic lipopolysaccharide and postnatal hyperoxia. J Perinat Med 2010; 38:675-81.
14. Kim DH, Choi CW, Kim EK, Kim HS, Kim BI, Choi JH, et al. Association of increased pulmonary interleukin-6 with the priming effect of intra-amniotic lipopolysaccharide on hyperoxic lung injury in a rat model of bronchopulmonary dysplasia. Neonatology 2010;98:23-32.
15. Stenmark KR, Abman SH. Lung vascular development: implications for the pathogenesis of bronchopulmonary dysplasia. Annu Rev Physiol 2005;67:623-61.
16. Hosford GE, Olson DM. Effects of hyperoxia on VEGF, its receptors, and HIF-2alpha in the newborn rat lung. Am J Physiol Lung Cell Mol Physiol 2003;285:L161-8.
17. Kunig AM, Balasubramaniam V, Markham NE, Seedorf G, Gien J, Abman SH. Recombinant human VEGF treatment transiently increases lung edema but enhances lung structure after neonatal hyperoxia. Am J Physiol Lung Cell Mol Physiol 2006;291:L1068-78.
18. Park HS, Park JW, Kim HJ, Choi CW, Lee HJ, Kim BI, et al. Sildenafil alleviates bronchopulmonary dysplasia in neonatal rats by activating the hypoxia-inducible factor signaling pathway. Am J Respir Cell Mol Biol 2013;48:105-13.
19. Biscetti F, Straface G, Pitocco D, Zaccardi F, Ghirlanda G, Flex A. Peroxisome proliferator-activated receptors and angiogenesis. Nutr Metab Cardiovasc Dis 2009;19:751-9.
20. Maniscalco WM, Watkins RH, Pryhuber GS, Bhatt A, Shea C, Huyck H. Angiogenic factors and alveolar vasculature: development and alterations by injury in very premature baboons. Am J Physiol Lung Cell Mol Physiol 2002;282:L811-23.
21. Thébaud B, Ladha F, Michelakis ED, Sawicka M, Thurston G, Eaton F, et al. Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: evidence that angiogenesis participates in alveolarization. Circulation 2005;112:2477-86.
22. Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA, Maniscalco WM. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;164(10 Pt 1):1971-80.
23. Thébaud B, Abman SH. Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease. Am J Respir Crit Care Med 2007;175:978-85.
24. Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 1999;354:141-8.
25. Yamakawa K, Hosoi M, Koyama H, Tanaka S, Fukumoto S, Morii H, et al. Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem Biophys Res Commun 2000;271:571-4.
26. Rehan VK, Torday JS. PPARγ Signaling Mediates the Evolution, Development, Homeostasis, and Repair of the Lung. PPAR Res 2012;2012:289867.
27. Torday JS, Torres E, Rehan VK. The role of fibroblast transdifferentiation in lung epithelial cell proliferation, differentiation, and repair in vitro. Pediatr Pathol Mol Med 2003;22:189-207.
28. Torday JS, Rehan VK. Stretch-stimulated surfactant synthesis is coordinated by the paracrine actions of PTHrP and leptin. Am J Physiol Lung Cell Mol Physiol 2002;283:L130-5.
29. Rehan VK, Fong J, Lee R, Sakurai R, Wang ZM, Dahl MJ, et al. Mechanism of reduced lung injury by high-frequency nasal ventilation in a preterm lamb model of neonatal chronic lung disease. Pediatr Res 2011;70:462-6.
30. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:79-82.
31. Corton JC, Anderson SP, Stauber A. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol 2000;40:491-518.
32. Escher P, Wahli W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res 2000;448:121-38.
33. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Maffia P, Patel NS, et al. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol 2004;483:79-93.
34. Rehan VK, Dargan-Batra SK, Wang Y, Cerny L, Sakurai R, Santos J, et al. A paradoxical temporal response of the PTHrP/PPARgamma signaling pathway to lipopolysaccharide in an in vitro model of the developing rat lung. Am J Physiol Lung Cell Mol Physiol 2007;293:L182-90.